Search

Novavax Inc

Fermé

SecteurSoins de santé

8.05 -1.11

Résumé

Variation du prix de l'action

24h

Actuel

Min

7.91

Max

8.1

Chiffres clés

By Trading Economics

Revenu

-44M

-53M

Ventes

-83M

57M

P/E

Moyenne du Secteur

3.112

57.002

BPA

-0.32

Marge bénéficiaire

-94.16

Employés

749

EBITDA

-39M

-40M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+62.78% upside

Dividendes

By Acuity

Prochains Résultats

5 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

83M

1.3B

Ouverture précédente

9.16

Clôture précédente

8.05

Sentiment de l'Actualité

By Acuity

36%

64%

130 / 340 Classement par Healthcare

Novavax Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 août 2026, 23:26 UTC

Novavax Inc. shares are trading roughly flat in after-market hours, remaining above the 20-day moving average and near the upper end of the one-month range.

13 août 2026, 19:16 UTC

Novavax Inc. shares are higher today, maintaining strength above the 20-day moving average despite rising initial jobless claims reported by the Labor Department.

12 août 2026, 23:31 UTC

Novavax Inc. shares are lower in after-market trading, reflecting a weaker trend despite earlier gains. The stock remains above its 20-day moving average.

11 août 2026, 23:51 UTC

Novavax Inc. shares are higher in after-market trading, maintaining a position above the 20-day moving average within its one-month trading range.

10 août 2026, 23:46 UTC

Novavax Inc. shares are lower in after-market trading, showing some volatility since Monday's close and remaining within the middle of their one-month trading range.

7 août 2026, 19:36 UTC

News

Novavax Inc shares are higher today, supported by $57 million in second-quarter revenue and ongoing discussions with Sanofi on a COVID-19/influenza vaccine.

6 août 2026, 23:01 UTC

News

Novavax Inc expects 2026 revenue of $235 million to $275 million. Shares are trading higher in after-market hours following the earnings call.

5 août 2026, 23:01 UTC

Novavax shares are higher in after-market trading, though they remain below the 20-day moving average amid weaker-than-expected U.S. job growth data.

4 août 2026, 23:36 UTC

Novavax Inc. shares are higher in after-market trading, despite remaining below their 20-day moving average. Broader market sentiment may support this upward movement.

3 août 2026, 23:46 UTC

News

Novavax Inc is advancing in after-market trading as it shifts focus to licensing its Matrix-M adjuvant, attracting positive retail investor sentiment ahead of earnings.

31 juil. 2026, 19:16 UTC

Novavax Inc. shares are lower today, reflecting a decline from Thursday's close amid rising bond yields and crude oil prices contributing to inflation concerns.

30 juil. 2026, 22:01 UTC

Novavax Inc. shares advanced in after-market trading, rebounding from earlier session lows, though they remain below the 20-day moving average.

29 juil. 2026, 23:06 UTC

Novavax Inc. shares are higher in after-market trading, gaining slightly since Wednesday's close, despite broader market weakness and significant declines over the past month.

28 juil. 2026, 16:06 UTC

Novavax Inc. shares are lower today, reflecting broader market declines amid investor caution ahead of earnings and the Federal Reserve's interest rate decision.

27 juil. 2026, 14:02 UTC

Novavax Inc shares are higher in pre-market trading, rising to $7.73. This increase occurs amid three consecutive lower session closes and mixed economic data.

24 juil. 2026, 18:46 UTC

Novavax Inc. shares are lower today, continuing a trend of declines following three consecutive sessions of lower closes and trading below the 20-day moving average.

23 juil. 2026, 09:01 UTC

Novavax Inc shares are higher in pre-market trading, reflecting upward momentum since Wednesday. Broader market sentiment remains positive amid rising Asian equity indices.

22 juil. 2026, 23:11 UTC

Novavax Inc. shares are higher in after-market hours, driven by strength in biotechnology stocks. The company remains below its 20-day moving average.

21 juil. 2026, 22:46 UTC

Novavax Inc. shares declined in after-market trading, remaining below their 20-day moving average despite a broader market rebound in the tech sector.

20 juil. 2026, 23:46 UTC

Novavax Inc. shares traded roughly flat after-market with no specific news identified. The stock remains significantly below its 20-day moving average.

Comparaison

Variation de prix

Novavax Inc prévision

Objectif de Prix

By TipRanks

62.78% hausse

Prévisions sur 12 Mois

Moyen 13.25 USD  62.78%

Haut 19 USD

Bas 7 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

4 ratings

2

Achat

1

Maintien

1

Vente

Sentiment

By Acuity

130 / 340Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat